EQ Equillium

Equillium to Participate in Upcoming Investor Conferences

Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:

Piper Sandler 37th Annual Healthcare Conference
Format:Fireside Chat & 1x1 Meetings
Date:Tuesday, December 2, 2025
Time:11:30 AM EST



Evercore ISI 8th Annual Healthcare Conference
Format:Fireside Chat & 1x1 Meetings
Date:Wednesday, December 3, 2025
Time:3:50 PM EST



Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.

Investors are invited to review the company corporate deck found on the , as well as the replay from the recent virtual .

About Equillium

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways. 

For more information, visit .

Investor Contact

PJ Kelleher

LifeSci Advisors, LLC





EN
20/11/2025

Underlying

EQEquillium

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Equillium

 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(...

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2026, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 32,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock optio...

10m 1 EN
 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results ...

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund operations into 2029 LA JOLLA, Calif, March 25, 2026 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disord...

March 25, 2026 1 EN
 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium to Participate in the 38th Annual Roth Conference

Equillium to Participate in the 38th Annual Roth Conference LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a bi...

March 18, 2026 1 EN
 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium Announces $35 Million Financing with RA Capital Management

Equillium Announces $35 Million Financing with RA Capital Management Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will provi...

March 13, 2026 1 EN
 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium to Participate in the Leerink Partners 2026 Global Healthcar...

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. Abou...

February 25, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch